Cellular reprogramming of adult somatic cells into induced pluripotent stem cells (iPSCs), their characterization as well as the optimization of reprogramming efficiency through novel methods for the future application of iPSCs in clinical regenerative me

将成年体细胞重编程为诱导多能干细胞（iPSC）是一种强大的方法，为未来的再生医学提供了新的选择。由于iPSC来源于受体患者的体组织，它们避免了胚胎干细胞（ESC）充满的两个主要问题：首先，破坏人类胚胎和卵母细胞的伦理问题，其次，受体患者对ESC的免疫反应和排斥。该项目的目标是使用非病毒方法从成人脂肪基质细胞（hASC）产生iPSC。hASC最近被引入作为患者特异性分化供体细胞的来源，用于重编程为多能的未分化状态。在该项目中，将使用网络通路分析和转录谱来表征hASC衍生的iPSC。此外，microRNA将被用作控制自我更新和分化的新工具，从而提高重编程效率。因此，该项目旨在通过新的策略提高iPSC生成的效率，并了解iPSC衍生物的命运和功能。这将有助于更好地理解基本的干细胞生物学，并促进干细胞研究在未来临床疾病治疗中的医学应用。该项目将在Joseph Wu教授（医学博士，博士）的实验室进行，他在干细胞研究领域拥有丰富的专业知识，这一点可以通过他在同行评议出版物方面的广泛记录以及他与国际公认的干细胞研究，细胞重编程和micoRNA专家的众多联系来证明。在Joseph Wu教授的实验室进行博士后研究期间获得的宝贵经验将使我能够在未来继续作为德国学术研究的知名科学家。

Reprogramming of adult somatic cells into induced pluripotent stem cells (iPSCs) is a powerful approach that offers new options for regenerative medicine in the future. Because iPSCs are derived from the somatic tissues of recipient patients, they avoid two major concerns that embryonic stem cells (ESCs) are fraught with: Firstly, the ethical concern of destroying human embryos and oocytes and secondly, the immunological response and rejection of ESCs by the recipient patient. The goal of this project is the generation of iPSCs from adult human adipose stromal cells (hASCs) using non-viral methods. hASCs have been recently introduced as a resource of patient-specific differentiated donor cells for reprogramming into a pluripotent, undifferentiated status. In this project, hASC-derived iPSCs will be characterized using network pathway analysis and transcriptional profiling. Moreover, microRNAs will be employed as a novel tool to control self-renewal and differentiation and hence to increase reprogramming efficiency. Thus this project aims at improving the efficiency of iPSCs generation through new strategies and to understand the fate and functionality of iPSC derivatives. This should contribute to both a better understanding of basic stem cell biology and to facilitating medical applications of stem cell research for clinical disease therapy in the future. This project will be performed in the laboratory of Prof. Joseph Wu (MD, PhD), who has great expertise in the field of stem cell research as demonstrated by his extensive record of peer-reviewed publications and his numerous connections to internationally recognized experts in stem cell research, cellular reprogramming and micoRNAs. The valuable experience obtained during this postdoctoral research sojourn abroad in the laboratory of Prof. Joseph Wu will prepare and enable me to continue in the future as an established scientist in academic research in Germany.